ACADIA Pharmaceuticals(ACAD) ZACKS·2024-12-03 15:55Core Insights - Zacks Premium provides various tools for investors to enhance their stock market strategies and confidence [1][2] Zacks Style Scores - Zacks Style Scores are indicators that rate stocks based on value, growth, and momentum methodologies, helping investors identify stocks likely to outperform in the next 30 days [3][4] - Stocks are rated from A to F, with A indicating the highest potential for outperformance [4] Categories of Style Scores - Value Score: Focuses on identifying undervalued stocks using ratios like P/E, PEG, and Price/Sales [5] - Growth Score: Analyzes projected and historical earnings, sales, and cash flow to find stocks with sustainable growth [6] - Momentum Score: Utilizes price trends and earnings estimate changes to identify favorable investment opportunities [7] - VGM Score: Combines all three Style Scores to highlight stocks with attractive value, growth forecasts, and momentum [8] Zacks Rank and Style Scores - The Zacks Rank is a proprietary model that uses earnings estimate revisions to assist in portfolio building [9] - Stocks rated 1 (Strong Buy) have historically produced an average annual return of +25.41% since 1988, significantly outperforming the S&P 500 [10] - Investors are encouraged to select stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B for optimal success [12] Example Company: Acadia Pharmaceuticals - Acadia Pharmaceuticals is a biopharmaceutical company focused on CNS disorders and rare diseases [15] - Currently rated 3 (Hold) with a VGM Score of B, Acadia has a Momentum Style Score of A and has seen a 13.6% increase in shares over the past four weeks [16] - Six analysts have raised earnings estimates for fiscal 2024, with the consensus estimate increasing by 0.73 per share, and an average earnings surprise of 54.1% [16][17]